Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12142185 | 0.83 | HCRTR1 (0.40) | HSP90AB1MAPTPOLBSMN1; SMN2LMNA | |
| SCHEMBL1366043 | 0.81 | MKNK1 (0.40) | HSP90AB1POLBSMN1; SMN2 | |
| SCHEMBL13690044 | 0.81 | HSP90AB1 (0.50) | HSP90AB1MAPTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL12143536 | 0.81 | HSP90AB1 (0.37) | HSP90AB1MAPTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL12142165 | 0.80 | LMNA (0.42) | HSP90AB1MAPTPOLBLMNAHSP90AA1 | |
| SCHEMBL1364993 | 0.79 | PTPN11 (0.39) | HSP90AB1MAPTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL16509717 | 0.77 | LMNA (0.35) | HSP90AB1MAPTALDH1A1LMNATP53 | |
| SCHEMBL3721054 | 0.76 | KDM4E (0.49) | HSP90AB1ALDH1A1POLBSMN1; SMN2ABL1 | |
| SCHEMBL12142168 | 0.69 | NR1H2 (0.44) | POLBSMN1; SMN2 | |
| SCHEMBL17592952 | 0.65 | SMYD3 (0.46) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | HSP90AB1 2651/4885MAPT 2278/4885ALDH1A1 134/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HSP90AB1 2957/4885MAPT 1563/4885ALDH1A1 148/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | HSP90AB1 2651/4885MAPT 2278/4885ALDH1A1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.